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Abstract
In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit over placebo in the primary
endpoint of coronary heart disease events. Increased levels of atherogenic homocysteine were observed in some patients
assigned to fenofibrate therapy but the molecular mechanisms behind this are poorly understood. Herein we investigated
HDL lipidomic profiles associated with fenofibrate treatment and the drug-induced Hcy levels in the FIELD substudy. We
found that fenofibrate leads to complex HDL compositional changes including increased apoA-II, diminishment of
lysophosphatidylcholines and increase of sphingomyelins. Ethanolamine plasmalogens were diminished only in a subgroup
of fenofibrate-treated patients with elevated homocysteine levels. Finally we performed molecular dynamics simulations to
qualitatively reconstitute HDL particles in silico. We found that increased number of apoA-II excludes neutral lipids from HDL
surface and apoA-II is more deeply buried in the lipid matrix than apoA-I. In conclusion, a detailed molecular
characterization of HDL may provide surrogates for predictors of drug response and thus help identify the patients who
might benefit from fenofibrate treatment.
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Introduction
Cardiovascular disease (CVD) events are responsible for 75–80% of
all mortalities in patients with diabetes [1]. Patients with type 2
diabetes commonly have atherogenic dyslipidaemia, characterized by
abnormalities in lipids and apolipoproteins, e.g., elevated triglycerides
(TGs), decreased high-density lipoprotein cholesterol (HDL-C), small
dense low-density lipoprotein (LDL) particles and increased apoB-100
to apoA-I ratio. Despite the unequivocal success of statin therapy to
reduce major cardiovascular events, considerable residual risk persists
in people with type 2 diabetes [2,3]. It is therefore necessary to target
the major components, i.e., high TGs and low HDL cholesterol in the
malignant diabetic dyslipidemia to further reduces CVD events.
Fibrates, peroxisome proliferator activated receptor a (PPARa)
agonists, are lipid lowering drugs which are recommended for
patients with atherogenic dyslipidemia [4,5]. The fibrate therapy is
a promising approach to reduce TGs, improve improve
distribution of LDL subpopulations and raise HDL-C. The
possibility of fibrate therapy to benefit patients with type 2
diabetes at high CVD risk was the rationale for the design of the
largest population-based fenofibrate study, Fibrate Intervention
and Event Lowering in Diabetes (FIELD) [6]. The FIELD study
recruited 9,795 patients, aged 50–75 years, irrespective of their
prior CVD history or gender. The patients were randomized for
micronised fenofibrate (200 mg/day) or placebo treatment in a
double-blinded design for a period of 5 years. Unexpectedly, the
fenofibrate study failed to achieve significant benefit over placebo
in the primary endpoint of non-fatal and fatal coronary heart
disease events, even though fenofibrate treatment significantly
reduced CVD events in patients with dyslipidemias. In the FIELD
study fenofibrate therapy decreased TGs by 29%, increased apoA-
II by 28% but unexpectedly changes in HDL-C and apoA-I were
minor showing barely 2% and 4% increases of HDL-C and apoA-
I as compared to placebo group [6]. In a FIELD substudy,
fenofibrate therapy induced notable changes in the distribution of
HDL subspecies [7]. Growing evidence suggests that atheropro-
tective nature of HDL subspecies depends on the particle
composition and size: apoA-I may be more effective than apoA-
II and the greater the size of HDL particle, the higher the
atheroprotective nature [7,8,9,10].
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observed in patients assigned to fenofibrate therapy [11]. In the
same study, a direct relationship between Hcy and apoA-II
changes was observed. Hcy is an atherogenic amino acid and its
high levels in blood are linked to increased incidence of CVD
events [12,13]. The effect of fenofibrate treatment on homocys-
teine levels is even more severe as compared to other fibrates [14].
Fibrate-induced increase of Hcy has raised the question whether
this may compromise some of the beneficial effects of fibrate
therapy on cardiovascular outcomes.
Traditional methods of lipoprotein analysis, which have relied
on analyses of total protein, phospholipids, free cholesterol (FCho),
cholesterol ester (ChoE) and TG content [15], cannot fully explain
dysilipidemia and related apolipoprotein changes. Recent advanc-
es in mass spectrometry (MS)-based analytical platforms and
related bioinformatics approaches have permitted the study of
lipids at the molecular level [16,17,18,19]. Molecular lipids may
serve as better markers for specific metabolic phenotypes such as
insulin resistance as compared to the total lipid class concentra-
tions [20].
Detailed studies involving lipid and apolipoprotein molecular
level information can contribute to better understanding of
complex assembly of lipoprotein particles such as HDL. For
example, we characterized the HDL lipid compositional differ-
ences in subjects with low and high HDL-cholesterol [21]. Using
the information of the lipid composition of HDL particles in the
two groups, HDL particles were then reconstituted in silico by
performing large scale molecular dynamics simulations. The data
from these simulations such as changes in lipid composition also
induce specific spatial distributions of lipids within the HDL
particles that may have important implications for HDL function.
We hypothesized that lipidomic study of HDL particles derived
from the FIELD substudy patients will help elucidate (1) the effect
of fenofibrate therapy in patients matched for Hcy levels, (2) the
effect of elevated Hcy response and (3) the association between the
Hcy response and fenofibrate therapy. Such study requires
application of statistical models that address the specific questions
related to Hcy and fenofibrate effects. Moreover, since fenofibrate
therapy also affects apolipoprotein (mainly apoA-II) content in
HDL particle, it is important to study the apolipoproteins and
their interactions with other molecular lipids in HDL particles to
better understand the complex structure of HDL in the context of
response to therapy.
Here we performed global lipidomic analysis of HDL fractions
in three groups of subjects: (1) High Hcy group representing
highest quartile levels of Hcy, (2) Low Hcy group representing
lowest quartile levels of Hcy and (3) placebo group, matching for
Hcy levels in Low Hcy group at the study close-out. We applied a
multivariate multi-way model to identify the effects of fenofibrate
treatment, Hcy level and the synergistic effect of fenofibrate and
Hcy. Based on the observed HDL compositional lipid and
apolipoprotein changes in different study groups, we then
performed large-scale molecular dynamic simulations to reconsti-
tute HDL particles in silico.
Results
Characteristics of the study subjects
Clinical and biochemical characteristics of the study groups are
shown in Table 1. Baseline and the study close-out samples for
each variable were examined in Low and High Hcy groups,
whereas in the placebo group only the study close-out samples
were examined.
The groups were well matched for lipid and apolipoprotein
levels at baseline. At the study close-out, apoA-I, HDL-C and TG
levels were similar among the three groups, whereas subjects in
both fenofibrate groups had higher apoA-II levels and lower apoA-
I/apoA-II ratio as compared to the placebo group. Interestingly,
in both fenofibrate groups apoA-I levels were comparable at
baseline and close-out. Plasma PLTP activity and serum PON-1
mass at baseline and close-out were similar in both fenofibrate
groups. At the study close-out PLTP activity and PON-1 mass in
Table 1. Clinical and biochemical characteristics of the study groups.
Fenofibrate Low Hcy Fenofibrate High Hcy Placebo
Baseline Close out Baseline Close out Close out
Gender (M/F) 14/3 - 10/6 - 13/1
BMI (kg/m
2) 29.5 (5.8) 29.5 (4.2) 32.1 (5.1) 30.4 (5.4) 31.4 (5.9)
Smokers 34431
Hcy (mmol/L) 9.9 (2.3) 13.2 (2) 13 (3)
# 27.4 (6.5)* 13.3 (0.7)
TC (mmol/L) 5.2 (0.5) 4.6 (0.9) 5 (0.4) 4.2 (0.6) 4.9 (0.4)
HDL-C (mmol/L) 1.1 (0.2) 1.1 (0.3) 1.1 (0.2) 1 (0.2) 1.2 (0.3)
Triglycerides (mmol/L) 1.6 (0.7) 1.4 (0.8) 1.9 (0.7) 1.4 (0.6) 1.6 (0.6)
ApoA-I (mg/dl) 102 (13.5) 102.4 (15.5) 103 (13.3) 106 (22.6) 102 (22.3)
ApoA-II (mg/dl) 24.3 (3.5) 29.9 (6.5)** 25.5 (4.9) 31.5 (5.1)** 24.8 (5.2)
ApoA-I/ApoA-II ratio 4.2 (0.4) 3.4 (0.3)** 4.1 (0.6) 3.3 (0.5)** 4.1 (0.5)
HDL Size(nm) 9.1 (2.7) 9.0 (3.4) 9.1 (2.7) 9.0 (3.7) 9.0 (6.2)
PLTP (nmol/ml/h) 5700 (1649) 5985 (1917) 6018 (1675) 5902 (1890) 7334 (1683)
PON-1 mass (mg/ml) 16.5 (8.9) 11.5 (11.2) 16.3 (5.7) 18.5 (6) 24.9 (14.6)
Values are mean6 SD;
#p=0.003 High Hcy vs Low Hcy at baseline;
*p,0.001 High Hcy vs Low Hcy and placebo at close out;
**p,0.05 Low Hcy vs placebo;
**p,0.05 High Hcy vs placebo; BMI=Body Mass Index; Hcy=homocysteine.
doi:10.1371/journal.pone.0023589.t001
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both fenofibrate groups.
We first applied multivariate multi-way modeling [22,23] to
identify the effects of covariates on clinical variables. The
interaction effect indicates whether fenofibrate has a differential
effect in Low and High Hcy groups. Our results confirmed the
increased Hcy levels due to fenofibrate treatment (Figure 1) and
the increase was even more pronounced for the High Hcy patients,
indicated by the positive term corresponding to the interaction of
fenofibrate and Hcy levels. Notably, among the HDL-associated
apolipoproteins, apoA-II was upregulated by fenofibrate.
Lipidomic analysis of HDL subfractions
Molecular lipid profiles of HDL particles derived from blood
samples collected at baseline and close-out were investigated by
using ultra performance liquid chromatography coupled to mass
spectrometry (UPLC-MS). A total of 615 lipid peaks were
detected, of which 249 were identified. Lipidomics data analysis
was performed using the multivariate multi-way analysis [22,23].
In order to reduce the number of variables as part of the modeling,
the method clustered the lipidomics data, resulting in 22 lipid
clusters (Table 2). The effects of covariates on the lipid clusters are
shown in Figure 2.
Fenofibrate treatment induced specific changes in multiple lipid
clusters. The main findings are summarized below:
N Sphingomyelin (SM)-rich clusters C9 and C15 were upregu-
lated due to fenofibrate effect.
N Phosphatidylcholine (PC) rich clusters C5 and C22 as well as
C10, C12 and C13 (mainly membrane and ether-linked lipids)
were upregulated by fenofibrate.
N Clusters C3 and C4, both including ether phospholipids, were
upregulated in the Low Hcy group due to fenofibrate effect;
this is indicated by the combination of a positive fenofibrate
effect and a negative interaction of fenofibrate and Hcy level.
N LysoPCs-specific cluster (C21) was down-regulated by fenofi-
brate effect.
N Cluster C18 with 5 unidentified lipids was down-regulated
similarly with each treatment.
N Three unidentified lipids were upregulated in C14 of the
placebo group.
We further examined lipid class-specific lipidomic profiles to
confirm the observed changes in the multivariate modeling results
and link them with specific lipid molecular changes (Figure 3).
LysoPCs were significantly diminished for both fenofibrate groups
as compared to placebo group at the study close-out, and this
effect was even stronger in High Hcy group. SM levels were
significantly elevated in both fenofibrate groups as compared to
placebo group at the close-out, and this effect was slightly stronger
for the Low Hcy group. Ethanolamine plasmalogen and ChoE
levels were elevated in Low Hcy group as compared to the levels in
high Hcy group.
In silico reconstitution of HDL particles – the effect of
drug induced lipid compositional changes
We then investigated whether the lipid compositional changes
induce specific structural differences to spherical HDL particles,
especially to the partitioning of different lipid constituents. The
change of SM-PC ratio in HDL particles is functionally relevant
since SMs are known to effectively solubilize cholesterol and form
liquid order phases with cholesterol molecules [24]. Therefore, an
increased SM-PC ratio in HDL particles could induce liquid
ordered domains in HDL particles, which in turn could affect
metabolism and function of HDL.
For the reasons above we carried out, similarly as in our earlier
study [21], three simulations to study the effect of SM/PC ratio to
the lipid partitioning without changing the phospholipid concen-
tration of particles. We also decreased the lysoPC concentration in
one simulation, although removing four lysoPCs from HDL
particles does not induce large differences to molecular distribu-
tion. The molecular compositions of different molecular dynamics
simulation runs are shown in Table 3.
We did not detect any marked differences in the localization of
TG and ChoE to particle surface monolayer implying that the
ratio of SM/PC is not so critical for the solubility of neutral core
lipids to surface monolayer in HDL particles (Figure 4). The
number of contacts between apoA-I and SM increased as a
function of SM concentration. In contrast, the contacts between
Figure 1. The effects of covariates on clinical variables. The effects fenofibrate (F), placebo (P) and interaction of fenofibrate and Hcy level (I)
are shown by box-plots for each clinical variable. Positive fenofibrate effect indicates that both Low Hcy and High Hcy groups are upregulated by
fenofibrate treatment. The combination of positive fenofibrate effect and positive interaction effect indicate that both Low Hcy and High Hcy groups
are upregulated by fenofibrate treatment and for the High Hcy groups the effect is even stronger. The box plots show quartiles and 95% intervals of
posterior mass of the effects; a posterior distribution above or below zero implies an effect is found. A positive effect (above zero) implies an
upregulation, a negative effect (below zero) implies a down-regulation. Significant and almost significant effects are highlighted in red and blue,
respectively.
doi:10.1371/journal.pone.0023589.g001
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separation in the current molecular dynamics simulations and
the preference of cholesterol molecules towards apoA-I did not
change. Consequently, the increase of number of contacts between
SM and apoA-I with increasing SM-PC ratio is trivial.
In silico reconstitution of HDL particles – the effect of
ApoAII
The number of apoA-II molecules differs between individuals in
different study groups (Table 1 and Figure 1). The role of apoA-II
in the structure of HDL and in HDL as well as in general
lipoprotein metabolism is currently poorly understood. We
therefore investigated the possible effect of apoA-II on the lipid
distribution in HDL particles. Since the amount of apoA-II
molecules increased in fenofibrate treated group (especially in Low
Hcy individuals), we carried out a simulation with HDL particles
composed of two apoA-Is and one apoA-II (lipid composition was
the same as in the MD-1 model shown in Table 3). Initially, we
placed apoA-II above HDL particle after which we carried out a
short vacuum simulation to get apoA-II attached to the surface of
HDL particle (Figure 5). Afterwards, we carried out apoA-II HDL
particle simulation in water. Snapshot from the end of simulations
at 12 ms shows that apoA-II adopted a V-shape-like conformation
on the surface of HDL particles and the double belt structure is
stable during the whole simulation. In addition, apoA-II did not
aggregate with apoA-Is, although the timescales of our simulations
is not enough to give reliable estimates of the possible interactions
between these proteins.
Next we calculated the number of TGs and ChoEs at the
particle surface. Total number of neutral lipids decreased since the
binding of apoA-II excluded some of ChoEs from the surface
monolayer (Figure 4). This observation is relevant because the
binding of apoA-II increases the lipid packing at the surface
inducing the exclusion of neutral lipids from the surface monolayer
of HDL since neutral lipids are more hydrophobic than
phospholipid and cholesterol molecules. Neutral lipids are known
to phase separate to phospholipid-air interface in Langmuir
monolayer studies with increasing surface pressure [25]. Thus, the
increased content of apoA-II in HDL particles increases the
surface pressure of amphiphilic monolayer surrounding the
hydrophobic core. We hypothesize that the modulation of surface
pressure of HDL particles by different apolipoproteins could
inhibit the binding of different proteins and enzymes to the HDL
surface. For example, it is well known that the addition of human
apoA-II to the HDL particle solution excludes human apoA-Is
from HDL particles [26,27]. Consequently, the apoA-II induced
remodeling of HDL particles would have marked effects to the
metabolism of HDL particles.
We analyzed the lipid affinities of apoA-I and apoA-II by
calculating the number of contacts between different lipids and
apoA-I/apoA-II. Number of contacts was divided by number of
amino acids in apoA-I or apoA-II to produce the lipids affinities per
amino acid since the number of amino acids in apoA-II is lower
compared to apoA-I. Results indicate that apoA-II has lower affinity
towards FCho, PC and SM molecules, but slightly higher affinity
towards ChoE as compared to apoA-I. This difference could be
Table 2. Description of lipid clusters obtained from multivariate multi-way analysis.
Cluster # of lipids* Summary Example of representative lipids
C1 37 HDL core lipids, mainly energy storage and dietary fat transporter lipids TG(54:3) and ChoE (18:2)
C2 22 Mainly energy storage lipids TG(50:5) and TG(56:9)
C3 42 Mainly abundant membrane and ether lipids PC(36:5) and PC(34:4e)
C4 76 Ether-linked and energy storage lipids PE(P-16:0/20:5) and TG(50:2)
C5 38 Mainly abundant membrane lipids PC(36:6) and PC (34:3)
C6 19 Mainly abundant membrane lipids PC(38:7) and PC(38:6)
C7 31 Energy storage and dietary fat transporter lipids TG(50:4) and TG(56:6)
C8 52 Energy storage and dietary fat transporter lipids TG(48:3) and TG(51:1)
C9 29 Signal transduction and membrane lipids SM(d18:1/22:0) and SM(d18:1/24:0)
C10 23 Membrane and ether lipids PE(38:4), PC(36:5) and PE(P-18:0/20:5)
C11 11 Membrane lipids and energy storage lipids PC(40:2) and TG(48:4)
C12 37 Mainly abundant phospholipids including ether-linked ones, as well
as dietary fat storage lipids
PE(P-18:0/22:6), PC(36:4e) and TG(53:8)
C13 11 Membrane lipids PE(36:4)
C14 3 Not identified -
C15 34 Mainly signal transduction and membrane lipids SM(d18:1/16:1) and SM(d18:1/18:0)
C16 17 Energy storage and dietary fat transporter lipids TG(58:9)
C17 20 Mainly phospholipids, and certain core lipid PC(36:5) and ChoE(20:5)
C18 5 Not identified -
C19 4 Not identified -
C20 40 Membrane lipids, ether-linked ethanolamine plasmalogens and HDL
core lipids
PC(38:6) , PE(P-16:0/22:6) and ChoE(22:6)
C21 12 Abundant and anti-inflammatory lipids LysoPC(22:0) and LysoPC(16:1)
C22 53 membrane and HDL core lipids PC(40:8) and ChoE(18:1)
*Including both identified and unidentified lipid peaks.
doi:10.1371/journal.pone.0023589.t002
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decreases the amount of protein surface that can interact with surface
lipids. However, at the same time the surface area that is exposed to
the core lipids is higher when compared to two individual monomers.
We also compared the binding depth of apoA-I and apoA-II by
calculating the radial distribution functions (RDFs) for different
molecules with respect to center of mass of HDL particles. RDF
profiles show that apoA-II is located deeper in the lipid matrix as
compared to apoA-Is, likely reflecting the more hydrophobic
nature of apoA-II (Figure 5). This finding suggests and agrees well
with previous studies that indicate that the dissociation constant
(Kd) of apoA-II is lower than Kd of apoA-I [28].
Discussion
Herein we explored for the first time the HDL molecular lipid
signatures of patients treated with fenofibrate as well as identified
the specific lipid species characteristic of high and low Hcy
response following the drug treatment. Lipidomic analysis revealed
that lysoPCs are diminished following the fenofibrate treatment
and that this effect is stronger in patients with high Hcy levels at
study close-out. Sphingomyelins (SMs) were upregulated due to
fenofibrate treatment. However, according to our molecular
dynamics simulations, the increase of SM-PC ratio did not induce
marked differences to the distribution of lipids and structure of
HDL particles and the solubility of neutral core lipids to surface
monolayer did not change with increasing SM-PC ratio. The
solubility of neutral lipids to particle surface is functionally
important as the amount and type (TG or ChoE) of neutral lipids
at the surface could modulate the rate of hydrolysis via the action
of hepatic lipase or transfer of neutral lipids that could play an
important role in HDL metabolism [29,30,31]. The higher the
TG content in HDL particle, the better the substrate properties for
phospholipid transfer protein (PLTP), which in turn leads to
    
  
Figure 2. The effects of covariates on clusters of lipids. The effects of fenofibrate (F), placebo (P) and interaction of fenofibrate and Hcy level (I)
are shown by box-plots for each cluster of lipids. The box plots show quartiles and 95% intervals of posterior mass of the effects; a posterior
distribution above or below zero implies an effect is found. Positive fenofibrate effect indicates that both Low Hcy and High Hcy groups are
upregulated by fenofibrate treatment. The combination of positive fenofibrate effect and negative interaction effect indicate that only the Low Hcy
group is upregulated by fenofibrate treatment.
doi:10.1371/journal.pone.0023589.g002
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of which are good acceptors of cholesterol from macrophage-foam
cells [32,33]. In addition, cholesterol molecules seem to have
similar affinity towards apoA-I regardless the increase of SM-PC
ratio. No phase separation was registered in simulations which is
little surprising as it is known that SM and cholesterol are able to
form liquid ordered domains [24]. However, HDL particles have
high curvature that could play a role in the partitioning behavior
of lipids. Also the known limitations of coarse-grained force field
could induce unnatural phase behavior of lipids.
ApoA-I is a known cofactor for lecithin-cholesterol acyltransfer-
ase (LCAT). Interestingly, Jones and colleagues have suggested
that the molecular components (PC and cholesterol molecules)
required for ChoE synthesis, must be located near the LCAT
 
 
 
 
Figure 3. The concentrations of individual lipid species in the different study groups. Individual lipids from different lipid classes are
shown: (A) lysophosphatidyl choline, (B) sphingomyelin, (C) ethanolamine plasmalogen and (D) cholesteryl ester. Data are shown in mean6SEM for
each lipid. Concentration values are expressed in mmol/l [lipid]/mg/dl [HDL protein]. Significance levels are shown as follows: * p,0.05 for Low Hcy
group vs. placebo group; ** p,0.01 for Low Hcy group vs. placebo group; # p,0.05 for Low Hcy group vs. High Hcy group; ## p,0.01 for Low Hcy
group vs. High Hcy group and ### p,0.001 for Low Hcy group vs. High Hcy group.
doi:10.1371/journal.pone.0023589.g003
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indicate that the activity of LCAT decreases when the concentra-
tion of SM increases in HDL particles [36,37] because LCAT is
not able to hydrolyze SM molecules to produce free fatty acids.
Consequently, the maturation rate of SM-rich HDL particles
could be slower than SM-poor HDL particles. This would also
affect HDL particle size by a shift towards smaller less protective
particles.
ApoA-II was elevated significantly in the fenofibrate-treated
individuals as compared to the placebo group. As a result of
PPARa-induced apoA-II gene transcriptionhepatic apoA-II pro-
duction and secretion are elevated [38], but the relevance of apoA-
II with respect to atherosclerosis is debated. Our simulation results
imply that the apolipoprotein content of HDL particles can
modulate the molecular packing at the particle surface, thus
affecting the number of neutral lipids at the surface lipid
monolayer. ApoA-II also expressed lower affinity towards SM,
PC and cholesterol molecules and higher towards ChoE as
compared to apoA-I. This may arise from the double-belt like
conformation of homodimer apoA-II that reduces the protein area
that can be in contact with surface lipids.
Based on our simulation results and earlier experiments we
propose that one possible role of apoA-II in HDL metabolism is to
modulate the molecular composition of surface monolayer of HDL
particles by excluding other apolipoproteins or neutral lipids from
the surface monolayer as it possesses higher lipid affinity compared
to other apolipoproteins. For example, apoA-IIs can exclude
apoA-Is from HDL particles because apoA-II possesses lower
dissociation constant [27,28,39,40,41] that is almost comparable
to apoB-100, which is known to be the sole non-exchangeable
apolipoprotein in circulation. Simulation data agree with this view
since apoA-II was shown to be more deeply buried in HDL
particles than apoA-I. Interestingly, apoA-II induced exclusion of
apoA-I from HDL could generate more lipid-poor apoA-I
Table 3. Molecular composition of different simulation runs.
SM:PC:FCho:lysoPC:ChoE:TG (number
of molecules per particle)
apoA-I (number of molecules
per particle)
apoA-II( number of molecules
per particle)
MD-1 18:109:50:10:90:19 2 0
MD-2 25:102:50:6:90:19 2 0
MD-3 47:80:50:6:90:19 2 0
MD-4 18:109:50:10:90:19 2 1
doi:10.1371/journal.pone.0023589.t003
Figure 4. Number of core lipids at the surface and contacts between proteins and different lipids. (A) Number of core lipids at the
surface of particles (number of contacts between water and neutral lipid ester beads). When compared to the control simulation (MD-1), the total
number of neutral lipids at the surface decreases in simulation MD-4 where the ratio of surface lipids (PC, SM, FCho and lysoPC) and apolipoprotein
residues is highest. Bar numbers show the percentage of total neutral lipids at the surface. (B) The number of contacts (per amino acid) between
apoA-I or apoA-II and different lipids in simulations. Notably, the affinity of apoA-I towards PC, SM, FCho, and lysoPC is stronger than apoA-IIs.
However, the affinity of ApoA-II is stronger towards ChoE compared to apoA-I. Affinities toward TG are same for both apolipoproteins. Errors bars are
standard deviations.
doi:10.1371/journal.pone.0023589.g004
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early steps of the reverse cholesterol transport. Our data suggests
that increase of apoA-II levels by fenofibrates explains, at least
partly, the lack of elevation of apoA-I in the circulation.
The mechanism by which fenofibrate increases Hcy levels is
poorly understood in humans. Fenofibrate is able to raise HDL-C
levels but to a variable degree of response [6,43,44]. The greater
the increase in Hcy levels the smaller is the increase in the HDL-C
levels in fenofibrate treated patients [11]. Identification and
understanding of the molecular factors behind the increase of Hcy
is clinically important since this may help identify the patients who
may benefit from the fenofibrate treatment. We observed that
several ether lipids including ethanolamine plasmalogens were
elevated in Low Hcy group as compared to High Hcy group due
to fenofibrate treatment. Reportedly HDL contains more
ethanolamine plasmalogens species compared to other lipoproteins
[12]. One of the functions of these plasmalogens is to act as
antioxidants and thus prevent the oxidation of cholesterol and
phospholipids [45]. Our data therefore suggests that the HDL
particles of patients who respond to fenofibrate therapy with
elevated Hcy have lower antioxidant capacity. Further studies are
needed to address this hypothesis.
As a potential limitation of our study, one has to keep in mind
that our simulation model may not represent the real structure of
HDL, since the physiological lipid and apolipoprotein composi-
tions of HDL particles are very heterogeneous. However, the in
silico approach is currently the only available strategy to assess the
HDL structure as dependent on lipid molecular changes. Lipid
spatial distributions and related trends are to be verified when such
experimental information can become available. Furthermore, our
findings are clinically relevant also due the unique design of the
present fenofibrate-interevention study which allows us to
investigate the effect of fenofibrate, placebo and the concerted
action of fenofibrate and Hcy.
In conclusion, our study shows that fenofibrate therapy leads to
complex compositional changes of HDL particles and that the
drug responses are different in patients with elevated Hcy as
compared to patients with normal or low Hcy levels following the
therapy. The in silico studies suggest that the observed
compositional changes lead to specific HDL structural changes,
with the major effect being linked to the elevated apoA-II level
that may also explain at least partly the neutral effect of
fenofibrate on apoA-I. The complexity of the fenofibrate response
regarding HDL, with some changes pro- and some anti-
atherogenic, may explain the heterogeneity of treatment benefits
of fibrates, the largest benefits of cardiovascular outcomes being
related to the magnitude of TG lowering reported in a recent
meta-analyses of fibrate trials [46]. Finally, the present study
suggests that more detailed molecular characterization of HDL
may provide surrogates for predictors of drug response and thus
help identify the patients who might benefit from fenofibrate
treatment.
Figure 5. Radial distribution functions of different molecules and snapshots from simualtions. (A) Radial distribution functions for TG,
ChoE, PC, apoA-II and apoA-I respect to the center of mass of HDL particle (MD-4). Distributions clearly indicate that apoA-II is more deeply buried
into lipid matrix. Inset shows a 2 nm slice from the center of HDL particle. Blue molecule is apoA-I, grey and red spheres are PCs, green ones are TGs,
and transparent and orange spheres are ChoEs. (B) Snapshots from simulation MD-4 showing the binding and conformation of apoA-II during
simulation MD-4. Top snapshot is from the start of short vacuum simulation. Middle one is from the start of water simulation. Bottom one is from the
end of simulation MD-4 showing V-conformation of apoA-II on the surface of HDL particle. PCs and SMs are rendered using grey spheres. Cholesteryl
esters and free cholesterol molecules are rendered using orange and yellow spheres, respectively. ApoA-II is rendered using brown spheres and
ApoA-I using blue spheres. Only backbone beads are rendered for clarity. Water and TG beads are not shown.
doi:10.1371/journal.pone.0023589.g005
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Study subjects
The FIELD study is a multinational study started in 1998 in
Australia, New Zealand and Finland [6]. In the FIELD Helsinki
center 270 type 2 diabetic patients were recruited. Of these
patients, after exclusion of statin and estrogen users, we selected 33
subjects in the fenofibrate group according to quartile levels of Hcy
at 5th year: 17 subjects were in the lowest quartile (Low Hcy) and
16 subjects were in the highest quartile (High Hcy). In addition, 14
subjects allocated to placebo were matched according to Hcy
levels at 5
th year to Low Hcy group. All the other details of the
study subjects are reported elsewhere [47]. Each study subject
gave written informed consent before participating in the study.
All samples were collected in accordance with the Helsinki
Declaration and the Ethics Committee of the Helsinki University
Central Hospital approved the study design.
Biochemical analyses
The baseline serum and plasma samples were collected during
the placebo run in period of the FIELD study before any
fenofibrate intervention. Serum total cholesterol, triglycerides,
HDL-C, LDL-C, apo B, apoA-I and apoA-II were analyzed as
described in detail [21]. PLTP activity was measured with a
radiometric assay [48]. Plasma homocysteine was determined by a
fluorescence polarization immunoassay (Abbott laboratories,
Abbott Park, IL, USA) and PON-1 mass using ELISA method
(Uscn Life Science Inc., Wuhan, China).
To analyze size distribution of HDL particles, HDL were
isolated by ultracentrifugation from 0.5 ml plasma or serum at
baseline and at close out and the run in native gradient PAGE
[49]. The mean HDL particle size was calculated by multiplying
the mean size of each HDL subclass by its relative area under the
densitometric scan [50]. The quantification of plasma preb-HDL
levels was performed by crossed immunoelectrophoresis [51].
Statistical analysis of primary clinical data
The statistical analysis was performed using SPSS 17.0 for
Windows (SPSS, Chicago, IL, USA). Data are expressed as mean
6 standard deviation Paired sample t test, ANOVA analysis of
variance and Kruskall Wallis tests were used for intra-group and
between groups comparisons. A p value of ,0.05 was considered
significant.
Lipidomic analysis
An internal standard mixture 1 was added to each sample of
total HDL fraction. The standard mixture contained lysoPC(17:0),
Cer(d18:1/17:0), PC(17:0/17:0), PE(17:0/17:0) and TG(17:0/
17:0/17:0) at a concentration level of 0.5–1 mg/sample. Lipids
were extracted with chloroform/methanol (2:1, v/v, 100 ml)
solvent. After vortexing (two min) and standing (one hour), the
samples were centrifuged at 10000 rpm for 3 min. The lower lipid
extract (60 ml ) was added with 10 ml of internal standard mixture
2 containing three labeled lipids: PC (16:1/0:0-D3), PC(16:1/16:1-
D6) and TG(16:0/16:0/16:0-
13C3).The samples order was rando-
mised before analysis by Waters Q-Tof Premier mass spectrometer
combined with an Acquity Ultra Performance LC
TM (UPLC). The
column (at 50uC) was an Acquity UPLC
TM BEH C18
2.16100 mm with 1.7 mm particles. The solvent system included
(A) Ultrapure water (1% 1 M NH4Ac, 0.1% HCOOH) and (B)
LC/MS grade acetonitrile/isopropanol (1:1, 1% 1 M NH4Ac,
0.1% HCOOH). The gradient started from 65% A/35% B,
reached 80% B in 2 min, 100% B in 7 min, and remained there
for 7 min. The flow rate was maintained at 0.400 ml/min and the
injected amount was 2.0 ml (Acquity Sample Organizer, at 10uC).
Reserpine was used as the lock spray reference compound. The
lipid profiling was carried out using ESI in positive mode and the
data was collected at a mass range of m/z 300–1200 with scan
duration of 0.2 sec.
The data processing using MZmine2 software [52] included
alignment of peaks, peak integration, normalization, and peak
identification. Lipids were identified using an internal spectral
library. The data was normalized using one or more internal
standards representatives of each class of lipid present in the
samples: the intensity of each identified lipid was normalized by
dividing it with the intensity of its corresponding standard and
multiplying it by the concentration of the standard. All monoacyl
lipids except cholesterol esters, such as monoacylglycerols and
monoacylglycerophospholipids, were normalized with PC(17:0/
0:0), all diacyl lipids except ethanolamine phospholipids were
normalized with PC(17:0/17:0), all ceramides with Cer(d18:1/
17:0), all diacyl ethanolamine phospholipids with PE(17:0/17:0),
and TG and cholesterol esters were normalized with TG(17:0/
17:0/17:0). Other (unidentified) molecular species were normal-
ized with PC(17:0/0:0) for retention time ,300 s, PC(17:0/17:0)
for retention time between 300 s and 410 s, and TG(17:0/17:0/
17:0) for higher retention times.
For further identification of unknown lipids, the sample was
analysed with UPLC instrument coupled to chip-based nanoelec-
trospray (TriVersa Nanomate, Advion Biosciences, Ithaca, NY)
and LTQ-Orbitrap mass spectrometer (Thermo Fischer Scientific,
San Jose, CA). Fractions (approximately 4 s each) were collected
from UPLC run using TriVersa Nanomate and the fractions
containing unidentified lipids were infused to a LTQ-Orbitrap
mass spectrometer by a TriVersa Nanomate in positive and
negative ionisation mode. Identifications were based on the exact
mass and MS
n spectra. The instrument was calibrated externally
according to the instructions of manufacturer. MS
2 and MS
3 were
acquired using either low resolution (LTQ) or high resolution up
to target mass resolution R=60,000 at m/z 400. The normalized
collision energies of 30–40% were applied in MS
n experiments.
Multivariate multi-way models
To analyze the effects of covariates on lipidomic profiles we
used a recently published methodology [22,23] developed to
extend ANOVA-type multivariate multi-way analysis to high-
dimensional, small sample-size setups. The method is particularly
suitable for analysing populations of high-dimensional lipidomics
(or other continuous-valued ‘omics’) profiles, where each sample
(individual patient) is associated to multiple covariates (such as
disease and treatment). The method assumes that there are
strongly correlated, similarly behaving clusters of lipids in the data,
and models the effects of the covariates and their interactions for
each cluster. The method is based on a unified Bayesian model, in
which both the clustering and of the multiple covariate effects are
estimated simultaneously.
There are several advantages in this modeling approach.
Modeling the effects of covariates on clusters of variables is an
excellent strategy against multiple testing problems. Secondly,
Bayesian methods take uncertainties in the data properly into
account which helps avoid over-fitting. In addition, the uncer-
tainty due to the small number of samples becomes evaluated and
reported properly. Finally, in contrast to resorting to a priori
defined clusters, such as gene sets in gene expression analyses, the
method finds the clusters as a part of the analysis, making it
possible to find novel clusters of lipids which both behave similarly
and are informative of the covariate effects.
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design that can be described as a linear model consisting of main
effects and interaction effects. In our dataset there are three groups
of individuals: low Hcy – fenofibrate, high Hcy – fenofibrate, and
low Hcy – placebo. The lipidomics profiles have been measured
before and after treatment. The experimental design is slightly
more complicated than the standard one assumed in [22] in two
respects: (1) There are no observations in the group high-Hcy-
placebo. The reason is that this group is biologically impossible:
placebo does not raise Hcy levels of any patients considerably. (2)
The measurements were taken from each patient before and after
the treatment, requiring a repeated measures treatment (pairwise
comparisons).
We extended the model to incorporate the two new assump-
tions, still allowing us to model the dataset within a single unified
model. The multi-way design including repeated-measures terms
was implemented as follows:
The multivariate multi-way model is a hierarchical Bayesian
model
xj*N(mzVxlat
j ,L);
and the effects of covariates operate on a latent factor space for
clusters of lipids, as explained in [22].
Before treatment:
Normal Hcy placebo: xlat
j ~tjze;
Normal Hcy fenofibrate: xlat
j ~tjze;
High Hcy fenofibrate: xlat
j ~tjze;
After treatment:
Normal Hcy placebo: xlat
j ~tjzPze;
Normal Hcy fenofibrate: xlat
j ~tjzFze;
High Hcy fenofibrate: xlat
j ~tjzFzIze;
where xj is a vector of concentrations of lipids for patient j, m is the
grand mean (average of lipid levels before treatment), V is the
projection matrix, L is a diagonal matrix of residual variances, xlat
j
is a latent factor for patient j, and e is a noise term. The tj is the
patient-specific effect for patient j, being the same before and after
treatment. The F is the fenofibrate effect, P is the placebo effect, I
is the interaction of fenofibrate and Hcy level.
In the standard formulation of repeated measures designs in
ANOVA-type linear models, a ‘‘patient-specific effect’’ term is
included into the model; this term is specific to the individual. The
ANOVA test for studying before/after-type of changes is stronger
when individual variation in samples has been modeled out with
such a term. Although repeated measures are a standard practice
in classical ANOVA studies, we are not aware of any work where
individual effects would have been included in Bayesian models
where the modeling is done in the latent variable space. We
implemented such a design and checked that it works well on data
with known effects.
The model parameters were estimated by Gibbs sampling
discarding 2000 burn-in samples and collecting 2000 Gibbs
samples. The optimal number of clusters was in the range of 20–
25, determined by predictive likelihood [22]. We used 25 clusters,
resulting in 22 non-empty clusters.
Construction of simulation systems and simulation
parameters
In order to study the effect of SM concentration to HDL
properties we used the end structure of our normal-HDL (we
refer to this MD-1 here) model from the previous simulation
study [21]. We randomly replaced PCs molecules by SM
molecules. In the first simulation we increased the number of
SMs by 30% and reduced the number of PCs by 6% and
lysoPCs by 30%. We refer to this simulation by MD-2. In
addition to this, we did additional simulation with 260%
increase of SM content and 27% decrease of PCs content to find
out if more pronounced SM content increase is able to change
the distribution and phase behavior of lipids in HDL particle
(MD-3). The exact particle numbers in simulations are shown in
Table 3.
For apoA-II simulation we also used the MD-1 as a starting
system. To this structure we directly incorporated apoA-II which
was coarse grained from the X-ray structure of aggregated apoA-II
[53]. We generated dimeric apoA-II where disulphide bond is
present between Cys-6 residues of each monomer. The secondary
structure of Apo-II was almost completely enforced to be alpha-
helical. However, coil regions were generated to the middle of
structure based on the information derived from X-ray structure
where a structural kink was present near residues 34–36. The
flexibility of alpha-helical segments arises from the three-body
angle and four-body dihedral potentials of backbone beads [54].
Dimeric apoA-II was placed near the surface of HDL particle so
that the hydrophobic side was pointing towards lipids and the
distance between lipid surface and N-terminal part of apoA-II was
approximately 0.5 nm. After the placement of apoA-II short
vacuum simulation were carried out to bind apoA-II to lipid
matrix. Afterwards system was solvated. Previously, we have used
similar approach to study lipid composition effects to spatial
distribution of lipids [21,55]. We refer to the apoA-II simulation
by MD-4.
All systems were first energy minimized by the steepest
descent algorithm. MD-2 and MD-3 simulations were simulat-
ed up to 2.5 ms, which corresponds to 10 msa n dm o r ea s
effective time since the MARTINI model speeds up the
d y n a m i c sb ya na p p r o x i m a t ef a c t o ro rf o u ro rm o r e[ 5 4 ] .L a s t
5 ms was used in the analysis. Production simulations for apoA-
II simulation MD-4 (non-fused) lasted for 3 ms, which
corresponds to 12 ms and more as effective time. System sizes
were approximately 26000 water beads and 5000 lipid and
protein beads in total. The box size in each non-fused
simulation was 15615615 nm.
Simulations were performed by the GROMACS simulation
package (v. 4.5.1) [56] and the standard Martini lipid force field
was used for PC (PC(16:0/18:1)), lysoPC (PC(16:0/0:0)), FCho
and SM (SM(d18:1/16:0)) molecules [57]. Protein part was
modeled using the protein extension of the Martini description
[54], TG (TG(18:1/18:1/18:1)) and ChoE (ChoE(18:1)) force
fields were constructed based on the philosophy of Martini force
field, the exact parameters and validation are available elsewhere
[55]. In all simulations temperature was set to 310 K and pressure
to 1 bar. Berendsen temperature and pressure coupling algorithms
[58] were utilized with coupling constants of 0.4 ps and 2.0 ps,
respectively. All lipid classes, protein residues and water were
separately coupled to heat bath. Electrostatic and Lennard-Jones
interactions were calculated using the shift type potentials with cut-
off lengths of 1.2 nm and the potentials were shifted to zero
starting at 0.0 and 0.9 nm, respectively. Time step was set to
0.025 ps. Systems were treated equilibrated when there was no
drift in number of contacts between apoA-I or apoA-II and
different lipids. In addition, there was no drift in the number of
contacts between ester bead regions of neutral lipids and water
molecules. We have to stress that conformation of proteins is not in
equilibrium but partitioning of helixes is broadened. Gromacs
analysis programs g_mindist and g_rdf were used in the analysis.
VMD was used to produce the figures from trajectory snapshots
[59].
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